stockportfolio.pro
Stocks / CBIO vs DNA
CBIO vs DNA
Crescent Biopharma, Inc. and Ginkgo Bioworks Holdings, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Crescent Biopharma, Inc. (CBIO) | Ginkgo Bioworks Holdings, Inc. (DNA) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $10.84M | $170.16M |
| Net income (latest FY) | $-153.94M | $-312.76M |
| Revenue growth (5y CAGR) | 1.3% | 17.3% |
| Net margin | -1419.6% | -183.8% |
| Return on equity | -75.8% | -61.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CBIO — free Open DNA — freeFrequently asked questions
Which is bigger, CBIO or DNA?
Ginkgo Bioworks Holdings, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, CBIO or DNA?
Over the last five fiscal years, Ginkgo Bioworks Holdings, Inc. grew revenue faster — 17.3%/yr versus 1.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.